Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival

Receptor tyrosine kinase AXL (RTK-AXL) is regarded as a suitable target in glioblastoma (GBM) therapy. Since AXL kinase inhibitors are about to get approval for clinical use, patients with a potential benefit from therapy targeting AXL need to be identified. We therefore assessed the expression patt...

Descripción completa

Detalles Bibliográficos
Autores principales: Onken, Julia, Vajkoczy, Peter, Torka, Robert, Hempt, Claudia, Patsouris, Victor, Heppner, Frank L., Radke, Josefine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper: Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584143/
https://www.ncbi.nlm.nih.gov/pubmed/28881571
http://dx.doi.org/10.18632/oncotarget.18468

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584143/
https://www.ncbi.nlm.nih.gov/pubmed/28881571
http://dx.doi.org/10.18632/oncotarget.18468

Ejemplares similares